ARIAD Pharmaceuticals, Inc. (Nasdaq ARIA) announced today that it proposes to offer 3,112,945 shares of its common stock pursuant to its effective shelf registration statements. The underwriter will be granted an option to purchase up to an additional 466,942 shares of ARIAD's common stock to cover over-allotments. All of the shares in the offering are being sold by ARIAD. Credit Suisse Securities (USA) LLC is acting as sole underwriter for the offering.

ARIAD is engaged in the discovery and development of breakthrough medicines to treat cancer by regulating cell signaling with small molecules.